<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974896</url>
  </required_header>
  <id_info>
    <org_study_id>20060134</org_study_id>
    <secondary_id>QUILT-2.016</secondary_id>
    <nct_id>NCT00974896</nct_id>
  </id_info>
  <brief_title>QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NantCell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NantCell, Inc.</source>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in
      combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects
      with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo
      cohorts are enrolling. All other combo cohorts are closed to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib or gemcitabine in subjects with advanced solid tumors</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacokinetic (PK) profiles of biologics or chemotherapy when used in combination with AMG 479</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumor response as assessed by World Health Organization (WHO) criteria</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumor response as measured by volumetric computed tomography (CT)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate anti-AMG 479 antibody response following AMG 479 administration</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>AMG 479 + Sorafenib cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 479 + Erlotinib cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 479</intervention_name>
    <description>AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).</description>
    <arm_group_label>AMG 479 + Erlotinib cohorts</arm_group_label>
    <arm_group_label>AMG 479 + Sorafenib cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved
             informed consent form

          -  Men and women ≥ 18 years old with a pathologically or cytologically documented,
             advanced solid tumor that is refractory to at least one line of therapy or for whom no
             standard therapy is available and for which no curative therapy is available, or the
             subject refuses standard non-curative therapy

          -  Measurable disease or evaluable disease per World Health Organization (WHO) guidelines

          -  Eastern Cooperative Oncology Group performance status ≤ 2

          -  Life expectancy of 3 months as documented by the investigator

          -  Adequate hematologic, renal and hepatic function

        Exclusion Criteria:

          -  Any co-morbid medical condition that would increase the risk of toxicity in the
             opinion of Investigator or Sponsor

          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved
             to Common Terminology Criteria for Adverse Events (CTCAE) grade 0 or 1, or to levels
             dictated in the inclusion/exclusion criteria with the exception of alopecia

          -  Subjects with primary or metastatic central nervous system (CNS) tumors are not
             allowed to enroll in the sorafenib cohorts. These subjects are allowed to enroll in
             the remaining cohorts, only if their CNS tumors have been controlled by prior surgery
             or radiation, and they have been neurologically stable

          -  History of lymphoma, leukemia, or high-dose chemotherapy with hematopoietic stem cell
             rescue

          -  Uncontrolled hypertension [diastolic &gt;100 mmHg or systolic &gt;150 mmHg]; Subjects
             enrolling in the sorafenib groups must not have diastolic &gt; 85 mmHg nor systolic &gt; 145
             mmHg

          -  Clinically significant ECG changes which obscure the ability to assess the PR, QT, QRS
             intervals

          -  Presence of ascites or pleural effusion requiring chronic medical intervention

          -  Diagnosis of arterial or venous thrombosis within 6 months before enrollment; history
             of bleeding diathesis

          -  History of clinically significant hypoglycemia or hyperglycemia in the opinion of the
             investigator

          -  Myocardial infarction within 6 months before enrollment, symptomatic congestive heart
             failure (New York Heart Association &gt;class II), unstable angina, or unstable cardiac
             arrhythmia requiring medication

          -  Active peptic ulcer disease

          -  History of chronic hepatitis

          -  Subject known to have tested positive for HIV

          -  Known sensitivity to mammalian derived products

          -  Hematological function, as follows:

          -  Absolute neutrophil count (ANC) ≤ 1.5 x 109/L for B, P, S and E cohorts

          -  Absolute neutrophil count (ANC) ≤ 3 x 109/L for G cohorts

          -  Platelet count ≤ 100 x 109/L

          -  Hemoglobin ≤ 9 g/dL

          -  Renal function, as follows:

          -  Calculated creatinine clearance &lt; 50 ml/min using the modified Cockroft-Gault equation

          -  Urinary protein quantitative value of &gt; 30 mg or &gt;1+ on dipstick, unless quantitative
             protein is &lt; 500 mg in a 24 hour urine sample

          -  Hepatic function, as follows:

          -  Aspartate aminotransferase (AST) &gt; 2.5 x upper limit of normal (ULN) (if liver
             metastases are present, ≥ 5 x ULN)

          -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN (if liver metastases are present, ≥ 5 x
             ULN)

          -  Alkaline phosphatase &gt; 2.0 x ULN (if bone or liver metastases are present, ≥ 5 x ULN)

          -  Bilirubin &gt; 2.0 x ULN

          -  Prothrombin time (PT) or partial thromboplastin time (PTT) &gt; 1.5 x ULN

          -  Treatment with anti-cancer therapy (6 weeks for nitrosoureas and mitomycin C
             chemotherapies), antibody therapy, retinoid therapy, or hormonal therapy within 4
             weeks before study day 1. Prior and concurrent use of hormone replacement therapy or
             the use of gonadotropin-releasing hormone (GnRH) modulators for prostate cancer are
             permitted

          -  Therapeutic or palliative radiation therapy within 4 weeks before enrollment (subjects
             must have resolution of any significant adverse effects from radiation therapy
             received prior to 2 weeks before enrollment)

          -  Concurrent or prior (within 1 week of study Day 1) anticoagulation therapy, except
             low-dose warfarin (≤ 2 mg/day) for prophylaxis against central venous catheter
             thrombosis

          -  Prior participation in clinical drug trials within 4 weeks before enrollment

          -  For subjects receiving erlotinib, the use of ketoconazole, clarithromycin,
             voriconazole, troleandomycin, telithromycin, rifabutin, rifapentine, phenytoin,
             carbamazepine, phenobarbital and St. John's Wort is prohibited

          -  For subjects receiving sorafenib, use of St. John's Wort, rifampin, phenytoin,
             carbamazepine, dexamethasone, and phenobarbital (CYP3A inducers) is prohibited

          -  Type 1 or 2 diabetics are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>AMG 479</keyword>
  <keyword>Amgen</keyword>
  <keyword>Oncology</keyword>
  <keyword>Phase 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

